Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | CASP7 | P55210 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 2/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894211 | 0.85 | TLR7 (0.41) | MAPTTSHRMEN1KMT2AMAPK1 | |
| SCHEMBL731277 | 0.84 | CASP1 (0.42) | MAPTTSHRMEN1KMT2AMAPK1 | |
| SCHEMBL1778208 | 0.84 | TLR7 (0.51) | MAPTTSHRMEN1KMT2AMAPK1 | |
| SCHEMBL5191474 | 0.78 | ADORA3 (0.40) | MAPTTSHRMEN1KMT2AMAPK1 | |
| SCHEMBL14323910 | 0.78 | CNR2 (0.45) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1897852 | 0.78 | ALDH1A1 (0.36) | MAPTTSHRMEN1KMT2AMAPK1 | |
| SCHEMBL1233428 | 0.76 | TLR7 (0.58) | MAPTMEN1KMT2ATLR8TLR7 | |
| SCHEMBL729372 | 0.76 | HPGD (0.61) | MAPTMEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL730935 | 0.75 | KDM4E (0.37) | MAPTTSHRMEN1KMT2AMAPK1 | |
| SCHEMBL728712 | 0.74 | KDM4E (0.36) | MAPTTSHRMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138173-B2 | Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138173-B2 | Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-20 | — | — | US | disclosed |
| US-7943636-B2 | 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090163533-A1 | 1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090069299-A1 | Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069299-A1 | Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1863814-A1 | 1-SUBSTITUTED PYRAZOLO (3,4-C) RING COMPOUNDS AS MODULATORS OF CYTOKINE BIOSYNTHESIS FOR THE TREATMENT OF VIRAL INFECTIONS AND NEOPLASTIC DISEASES | Coley Pharmaceutical Group, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006107851-A1 | 1-SUBSTITUTED PYRAZOLO (3,4-C) RING COMPOUNDS AS MODULATORS OF CYTOKINE BIOSYNTHESIS FOR THE TREATMENT OF VIRAL INFECTIONS AND NEOPLASTIC DISEASES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069299-A1 | Pyrazolo[3,4-c]Quinolines, Pyrazolo[3,4-c]Naphthyridines, Analogs Thereof, and Methods | IL4, IL2, IL5 | MAPT 4124/4885TSHR 3315/4885MEN1 3427/4885 |
| US-20090163533-A1 | 1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases | IL2, IL4, IFNG | MAPT 4203/4885TSHR 3370/4885MEN1 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.